Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120406 · ClinicalTrials.gov registry record · NA
Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
A NA study, sponsored by Cook Group Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 474
- Enrollment target
NCT00120406 is a NA study that has completed, run by Cook Group Incorporated. The registered enrollment target is 474 participants.
The verdict
NCT00120406, a NA study, has completed, sponsored by Cook Group Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 474 participants
- Enrollment target
Study Summary
The Zilver® PTX™ Drug Eluting Vascular Stent is indicated for the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery (ranging from 4 mm to 9 mm in reference vessel diameter) for lesions up to 7 cm long. The clinical trial is stratified by lesion length. The trial will be conducted in 2 phases, with Phase 1 enrolling patients with lesions less than 7 cm long. Phase 2 of the trial will include longer lesions (up to 14 cm long) and will be initiated upon approval by the Food and Drug Administration (FDA).
Interventions
- PROCEDURE Angioplasty
- DEVICE Zilver® PTX™ Drug Eluting Vascular Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2005-03 |
| Est. Completion | 2014-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120406
The ClinicalTrials.gov registry entry for NCT00120406 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook Group Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Angioplasty is the first listed.
NCT00120406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00120406 about?
NCT00120406 is a clinical study titled "Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery". The Zilver® PTX™ Drug Eluting Vascular Stent is indicated for the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery (ranging from 4 mm to 9 mm in reference vessel diameter) for lesions up to 7 cm long. The clinical trial is stratified by lesion length. The trial ...
What is the current status of trial NCT00120406?
This trial is currently completed. It is a NA study. The enrollment target is 474 participants. The study started on 2005-03. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00120406?
The interventions under investigation include: Angioplasty (PROCEDURE), Zilver® PTX™ Drug Eluting Vascular Stent (DEVICE).
Who is sponsoring clinical trial NCT00120406?
This trial is sponsored by Cook Group Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.